InĂªs Martins, PhD, managing science editor —

InĂªs holds a PhD in biomedical sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied cell and molecular biology and worked as a research fellow at multiple institutes. In addition to several college awards, InĂªs won the Pfizer Basic Research Award in 2012 for a research paper. She also has a graduate degree in data science.

Articles by InĂªs Martins

Liquidia to Expand PAH Treatment Efforts With RareGen Acquisition

Liquidia Technologies, a company developing an inhaled form of treprostinil for pulmonary arterial hypertension (PAH), has established an agreement to acquire the rare disease company and marketer of generic treprostinil injections, RareGen, strengthening the company’s efforts in the PAH field. Under the agreement, the two companies will…

Computer Model Seen to Accurately Distinguish PAH From PVOD

Gene expression patterns in the lungs can help distinguish pulmonary arterial hypertension (PAH) from pulmonary veno-occlusive disease (PVOD) — a subtype in which the narrowing of veins, instead of arteries, causes pulmonary hypertension — with high accuracy, a study reported. Findings also showed that lung diseases share similar alterations…

Aerami, Vectura Sign Deal to Develop Nebulized Imatinib

Aerami Therapeutics has entered an agreement with Vectura Group to develop and commercialize an inhaled form of imatinib — an approved cancer therapy — for the treatment of people with pulmonary arterial hypertension (PAH). Under the agreement, Aerami will be solely responsible for developing this new…

LENUS Pro Pump for Remodulin May Need Monitoring of Flow Rate

Tricumed‘s LENUS Pro pump, an implantable device approved in Europe for the long-term intravenous administration of Remodulin (treprostinil) to treat pulmonary arterial hypertension (PAH), does not maintain a steady flow rate over time, a study of refill data reports. The analysis found flow rates lower than those specified by…

In Certain CTEPH Patients, Vascular Remodeling May Lead to Hypoxemia

Patients with chronic thromboembolic pulmonary hypertension (CTEPH) who are successfully treated with pulmonary endarterectomy (PEA) may be at increased risk of having low levels of oxygen in the blood due to severe pulmonary arteriopathy, a condition characterized by pulmonary artery remodeling, according to a study from Chiba University in Japan. The…

Reata Releases Update on Clinical Program, Including Phase 2 Study in PH and PAH Patients

Reata Pharmaceuticals recently provided an update on its clinical candidates and their developmental, including its Phase 2 proof-of-concept studies into bardoxolone methyl as a potential treatment for various types of pulmonary hypertension and omaveloxolone for neuromuscular diseases. Bardoxolone methyl is being developed for patients with pulmonary arterial hypertension (PAH), or high…


A Conversation With Rare Disease Advocates